The Utility of the BRCAvantage Test

Article

Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.

Clinical Pearls

Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.

  • BRCAvantage was launched in mid-October
  • The test is a comprehensive solution to help patients and healthcare providers make clinical decisions regarding the prognostic nature of their disease course and treatment interventions
  • BRCAvantage includes a complete analysis of BRCA1 and BRCA2 as well as targeted tests for other specific gene mutations and family gene mutations

<<<

Back to the conference page

Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content